Cathepsin K in Pathological Conditions and New Therapeutic and Diagnostic Perspectives

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Nov 26

PMID 36430239

Authors

Olja Mijanovic

Aleksandra Jakovleva

Ana Brankovic

Kristina Zdravkova

Milena Pualic

Tatiana A Belozerskaya

Angelina I Nikitkina

Alessandro Parodi

Andrey A Zamyatnin Jr

Affiliations

Soon will be listed here.

Abstract

Cathepsin K (CatK) is a part of the family of cysteine proteases involved in many important processes, including the degradation activity of collagen 1 and elastin in bone resorption. Changes in levels of CatK are associated with various pathological conditions, primarily related to bone and cartilage degradation, such as pycnodysostosis (associated with CatK deficiency), osteoporosis, and osteoarthritis (associated with CatK overexpression). Recently, the increased secretion of CatK is being highly correlated to vascular inflammation, hypersensitivity pneumonitis, Wegener granulomatosis, berylliosis, tuberculosis, as well as with tumor progression. Due to the wide spectrum of diseases in which CatK is involved, the design and validation of active site-specific inhibitors has been a subject of keen interest in pharmaceutical companies in recent decades. In this review, we summarized the molecular background of CatK and its involvement in various diseases, as well as its clinical significance for diagnosis and therapy.

Citing Articles

The Impact of BMI on PCOS Patients and Transcriptome Profiling and Bioinformatic Analysis of Granulosa Cells in PCOS Patients with High and Low BMI.

Tao P, Yan X, Li Y, Wang Z Reprod Sci. 2025; .

PMID: 39821799 DOI: 10.1007/s43032-024-01783-6.

Review of Cathepsin K Inhibitor Development and the Potential Role of Phytochemicals.

Moon D Molecules. 2025; 30(1.

PMID: 39795149 PMC: 11721202. DOI: 10.3390/molecules30010091.

Harnessing curcumin and nanotechnology for enhanced treatment of breast cancer bone metastasis.

Shakori Poshteh S, Alipour S, Varamini P Discov Nano. 2024; 19(1):177.

PMID: 39527354 PMC: 11554965. DOI: 10.1186/s11671-024-04126-1.

Lysosomal Proteases and Their Inhibitors.

Turk V, Stoka V Int J Mol Sci. 2024; 25(18).

PMID: 39337555 PMC: 11432586. DOI: 10.3390/ijms251810070.

Lysosomal biogenesis and function in osteoclasts: a comprehensive review.

Jiang J, Ren R, Fang W, Miao J, Wen Z, Wang X Front Cell Dev Biol. 2024; 12:1431566.

PMID: 39170917 PMC: 11335558. DOI: 10.3389/fcell.2024.1431566.

References

Mohamed M, Sloane B . Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 2006; 6(10):764-75. DOI: 10.1038/nrc1949. View

Mano H, Yuasa T, Kameda T, Miyazawa K, Nakamaru Y, Shiokawa M . Mammalian mature osteoclasts as estrogen target cells. Biochem Biophys Res Commun. 1996; 223(3):637-42. DOI: 10.1006/bbrc.1996.0947. View

Migliore A, Paoletta M, Moretti A, Liguori S, Iolascon G . The perspectives of intra-articular therapy in the management of osteoarthritis. Expert Opin Drug Deliv. 2020; 17(9):1213-1226. DOI: 10.1080/17425247.2020.1783234. View

Calio A, Mengoli M, Cavazza A, Rossi G, Ghimenton C, Brunelli M . Cathepsin K expression in clear cell "sugar" tumor (PEComa) of the lung. Virchows Arch. 2018; 473(1):55-59. DOI: 10.1007/s00428-018-2325-1. View

Brubaker K, Vessella R, True L, Thomas R, Corey E . Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res. 2003; 18(2):222-30. DOI: 10.1359/jbmr.2003.18.2.222. View

Trindade F, Ferreira R, Amado F, Vitorino R . Biofluid proteases profiling in diabetes mellitus. Adv Clin Chem. 2015; 69:161-207. DOI: 10.1016/bs.acc.2014.12.004. View

Thompson S, Halbert S, Bossard M, Tomaszek T, Levy M, Zhao B . Design of potent and selective human cathepsin K inhibitors that span the active site. Proc Natl Acad Sci U S A. 1998; 94(26):14249-54. PMC: 24926. DOI: 10.1073/pnas.94.26.14249. View

Hao L, Zhu G, Lu Y, Wang M, Jules J, Zhou X . Deficiency of cathepsin K prevents inflammation and bone erosion in rheumatoid arthritis and periodontitis and reveals its shared osteoimmune role. FEBS Lett. 2015; 589(12):1331-1339. PMC: 4623593. DOI: 10.1016/j.febslet.2015.04.008. View

Podgorski I, Linebaugh B, Koblinski J, Rudy D, Herroon M, Olive M . Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. Am J Pathol. 2009; 175(3):1255-69. PMC: 2731144. DOI: 10.2353/ajpath.2009.080906. View

10.

Haeckel C, Krueger S, Kuester D, Ostertag H, Samii M, Buehling F . Expression of cathepsin K in chordoma. Hum Pathol. 2000; 31(7):834-40. DOI: 10.1053/hupa.2000.8448. View

11.

Everts V, Jansen I, de Vries T . Mechanisms of bone resorption. Bone. 2022; 163:116499. DOI: 10.1016/j.bone.2022.116499. View

12.

Khoshdel A, Forootan M, Afsharinasab M, Rezaian M, Abbasifard M . Assessment of the circulatory concentrations of cathepsin D, cathepsin K, and alpha-1 antitrypsin in patients with knee osteoarthritis. Ir J Med Sci. 2022; 192(3):1191-1196. DOI: 10.1007/s11845-022-03061-3. View

13.

Bitu C, Kauppila J, Bufalino A, Nurmenniemi S, Teppo S, Keinanen M . Cathepsin K is present in invasive oral tongue squamous cell carcinoma in vivo and in vitro. PLoS One. 2013; 8(8):e70925. PMC: 3737264. DOI: 10.1371/journal.pone.0070925. View

14.

Wu H, Du Q, Dai Q, Ge J, Cheng X . Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases. J Atheroscler Thromb. 2017; 25(2):111-123. PMC: 5827079. DOI: 10.5551/jat.RV17016. View

15.

Rao Q, Cheng L, Xia Q, Liu B, Li L, Shi Q . Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas): a clinicopathological study emphasizing extrarenal PEComas. Histopathology. 2013; 62(4):642-50. DOI: 10.1111/his.12059. View

16.

Aguda A, Panwar P, Du X, Nguyen N, Brayer G, Bromme D . Structural basis of collagen fiber degradation by cathepsin K. Proc Natl Acad Sci U S A. 2014; 111(49):17474-9. PMC: 4267343. DOI: 10.1073/pnas.1414126111. View

17.

Cawley K, Bustamante-Gomez N, Guha A, MacLeod R, Xiong J, Gubrij I . Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption. Cell Rep. 2020; 32(10):108052. PMC: 7493998. DOI: 10.1016/j.celrep.2020.108052. View

18.

Mukherjee K, Chattopadhyay N . Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy. Biochem Pharmacol. 2016; 117:10-9. DOI: 10.1016/j.bcp.2016.04.010. View

19.

Reithmeier A, Norgard M, Ek-Rylander B, Nareoja T, Andersson G . Cathepsin K regulates localization and secretion of Tartrate-Resistant Acid Phosphatase (TRAP) in TRAP-overexpressing MDA-MB-231 breast cancer cells. BMC Mol Cell Biol. 2020; 21(1):15. PMC: 7081696. DOI: 10.1186/s12860-020-00253-6. View

20.

Oso B, Adeoye A, Olaoye I . Pharmacoinformatics and hypothetical studies on allicin, curcumin, and gingerol as potential candidates against COVID-19-associated proteases. J Biomol Struct Dyn. 2020; 40(1):389-400. DOI: 10.1080/07391102.2020.1813630. View